Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
03 Septiembre 2024 - 3:30PM
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS),
a clinical-stage biotechnology company using its pioneering
gene-editing platform to develop life-saving cell and gene
therapies, today published a scientific article in Science Advances
suggesting that TALEN®-edited MUC1 CAR T-cells could be a potential
treatment option for advance-stage triple negative breast cancer
(TNBC) patients with limited therapeutic options.
Globally, breast cancer continues to be the most
prevalent malignancy in women. Among all subtypes, triple-negative
breast cancer (TNBC) stands out as the most aggressive form with
high metastatic potential and poor survival rates.
Despite a few emerging targeted therapies under
investigation, surgery, chemotherapy and radiation therapy continue
to be the standard of care, and their success remains limited. As
an alternative, Chimeric Antigen Receptor (CAR) T-cell therapies
could hold promise for advance-stage TNBC patients as
tumor-associated MUC1 antigen is overexpressed in a large number of
patients thus offering a distinct target for treatment.
In this article, Cellectis described its
multi-layered CAR T-cell engineering strategy using TALEN® and
synthetic biology to multi-armor CAR T-cells with synergistic
functionalities to overcome the immunosuppressive tumor
microenvironment (TME) of solid tumors. With this strategy,
Cellectis demonstrates enhanced cytotoxic activity of MUC1 CAR
T-cells armored with PD1KO, tumor-specific IL12 release and
TGFBR2KO attributes, all of them catered towards the TNBC TME, in
intravenous and intratumoral mouse models.
“Complexity of solid tumors decreases the
efficacy of CAR T-cell therapies. With this pre-clinical study, we
showed that TALEN®-mediated multiplex editing can support CAR
T-cells in effectively mounting an anti-tumor response to clear
breast tumors, and that we can further decrease the dose of the
treatment by injecting the CAR T cells intratumorally while still
treating distant tumors. This innovative approach also allowed us
to discover an unexpected cooperation between the edits in
increasing safety, highlighting the potential capabilities of
multiplex editing” said Piril Erler, PhD, Scientist II at
Cellectis.
Importantly, intratumoral treatment effectively
reduced local and distant tumors of large size using low doses of
multi-armored MUC1 CAR T-cells. This pre-clinical data suggests
that the benefits of antigen recognition are maintained at distant
sites and highlights the potential to address metastasis with local
administration.
The article is available on Science Advances’
website by clicking on this
link: https://www.science.org/doi/10.1126/sciadv.adn9857
About Cellectis
Cellectis is a clinical-stage biotechnology
company using its pioneering gene-editing platform to develop
life-saving cell and gene therapies. Cellectis utilizes an
allogeneic approach for CAR T immunotherapies in oncology,
pioneering the concept of off-the-shelf and ready-to-use
gene-edited CAR T-cells to treat cancer patients, and a platform to
make therapeutic gene editing in hemopoietic stem cells for various
diseases. As a clinical-stage biopharmaceutical company with 25
years of experience and expertise in gene editing, Cellectis is
developing life-changing product candidates utilizing TALEN®, its
gene editing technology, and PulseAgile, its pioneering
electroporation system to harness the power of the immune system in
order to treat diseases with unmet medical needs. Cellectis’
headquarters are in Paris, France, with locations in New York, New
York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq
Global Market (ticker: CLLS) and on Euronext Growth (ticker:
ALCLS).
To find out more, visit our
website: www.cellectis.com
Follow Cellectis on social networks @cellectis
on LinkedIn and X (formerly Twitter)
TALEN® is a registered trademark owned by
Cellectis.
Forward-looking Statements
This press release contains “forward-looking”
statements within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by words such as
“"can,” “possibility,” and “suggest” or the negative of these and
similar expressions. These forward-looking statements, which are
based on our management’s current expectations and assumptions and
on information currently available to management, include
statements about the potential of the product candidate MUC1, and
reproducibility of these preclinical data on humans. These
forward-looking statements are made in light of information
currently available to us and are subject to numerous risks and
uncertainties, including with respect to the numerous risks
associated with biopharmaceutical product candidate development.
Furthermore, many other important factors, including those
described in our Annual Report on Form 20-F and the financial
report (including the management report) for the year ended
December 31, 2023 and subsequent filings Cellectis makes with the
Securities Exchange Commission from time to time, as well as other
known and unknown risks and uncertainties may adversely affect such
forward-looking statements and cause our actual results,
performance or achievements to be materially different from those
expressed or implied by the forward-looking statements. Except as
required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
For further information on Cellectis, please
contact:
Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14
33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77
46 93
Investor Relations contact:
Arthur Stril, Interim Chief Financial Officer, +1 (347) 809
5980, investors@cellectis.com
Cellectis (NASDAQ:CLLS)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Cellectis (NASDAQ:CLLS)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024